← Back to Search

CAR T-cell Therapy

magrolimab, rituximab, and radiation, CAR T leukapheresis for Non-Hodgkin's Lymphoma

Phase 2

Waitlist Available

Led By Paolo Strati, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average of 1 year

Awards & highlights

Study Summary

This trial tests if a combination of drugs and radiation can help people with a type of lymphoma before they get CAR-T cell therapy.

Eligible Conditions

Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Design

1Treatment groups

Experimental Treatment

Group I: magrolimab, rituximab, and radiation, CAR T leukapheresisExperimental Treatment4 Interventions

Participants may receive radiation therapy at any time during the study. Participants will be given Magrolimab by vein once weekly for 4 doses by vein on an outpatient basis over about 180 minutes starting on Day 1 of Cycle 1. Participants will be given Rituximab by vein once weekly for 4 doses over about 3-4 hours starting on Day 1 of Cycle 1. You will be given rituximab about 30 minutes (no more than 90 minutes) after magrolimab therapy finishes. Participants will receive 1 dose of magrolimab and rituximab by vein one week before your CAR T leukapheresis and then 3 weekly doses of each drug starting 1 day after leukapheresis that will complete 1 week before lymphodepleting chemotherapy for CAR T

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Radiation

2003

Completed Phase 3

~1020

Rituximab

1999

Completed Phase 4

~1880

Magrolimab

2021

Completed Phase 2

~170

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,789,476 Total Patients Enrolled

Paolo Strati, MDPrincipal InvestigatorM.D. Anderson Cancer Center

3 Previous Clinical Trials

109 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently an open enrollment for participants in this experiment?

"According to the clinicaltrials.gov database, this trial is presently not taking on new patients. It was originally listed on September 30th 2023 and last edited on June 29th of the same year. Despite its current status as inactive, there are a plethora of alternative trials actively registering participants at this time – 1719 in total!"

Answered by AI

How secure are magrolimab, rituximab, radiation CAR T leukapheresis procedures for individuals?

"Our assessment of the safety profile of magrolimab, rituximab, and radiation along with CAR T leukapheresis is a 2 due to this being a Phase II trial. Thus far there has been evidence collected in support for its safety but not efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

2023. "An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05929716.